Maurer TS, Smith D, Beaumont K, Di L. Dose predictions for drug design. J Med Chem. 2020;63(12):6423–35. https://doi.org/10.1021/acs.jmedchem.9b01365.
Lucas AJ, Sproston JL, Barton P, Riley RJ. Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery. Expert Opin Drug Discov. 2019;14(12):1313–27. https://doi.org/10.1080/17460441.2019.1660642.
Reichel A, Lienau P. Pharmacokinetics in drug discovery: an exposure-centered approach to optimizing and predicting drug efficacy and safety. Handb Exp Pharmacol. 2016;232:235–60. https://doi.org/10.1007/164_2015_26.
Sundqvist M, Lundahl A, Nagard MB, Bredberg U, Gennemark P. Quantifying and communicating uncertainty in preclinical human dose-prediction. CPT Pharmacometrics Syst Pharmacol. 2015;4(4):243–54. https://doi.org/10.1002/psp4.32.
Varma MV, Steyn SJ, Allerton C, El-Kattan AF. Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS). Pharm Res. 2015;32(12):3785–802. https://doi.org/10.1007/s11095-015-1749-4.
Camenisch G, Riede J, Kunze A, Huwyler J, Poller B, Umehara K. The extended clearance model and its use for the interpretation of hepatobiliary elimination data. ADMET & DMPK. 2015;3(1):1–14. https://doi.org/10.5599/admet.3.1.144.
Chung TDY, Terry DB, Smith LH. In vitro and in vivo assessment of ADME and PK properties during lead selection and lead optimization - guidelines, benchmarks and rules of thumb. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, et al. editors. Assay Guidance Manual. Bethesda (MD) 2004.
Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27(11):1350–9.
Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res. 2005;22(1):103–12. https://doi.org/10.1007/s11095-004-9015-1.
Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 1982;10(2):201–27. https://doi.org/10.1007/BF01062336.
Mahmood I, Martinez M, Hunter RP. Interspecies allometric scaling. Part I: prediction of clearance in large animals. J Vet Pharmacol Ther. 2006;29(5):415–23. https://doi.org/10.1111/j.1365-2885.2006.00786.x.
Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos. 2007;35(10):1886–93. https://doi.org/10.1124/dmd.107.016188.
Liu D, Song H, Song L, Liu Y, Cao Y, Jiang J, et al. A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. Xenobiotica. 2016;46(12):1105–11. https://doi.org/10.1080/00498254.2016.1205761.
Wood FL, Houston JB, Hallifax D. Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocytes/microsomes and implications for experimental methodology. Drug Metab Dispos. 2017;45(11):1178–88. https://doi.org/10.1124/dmd.117.077040.
Sodhi JK, Benet LZ. Successful and unsuccessful prediction of human hepatic clearance for lead optimization. J Med Chem. 2021;64(7):3546–59. https://doi.org/10.1021/acs.jmedchem.0c01930.
Rowland M, Pang KS. Hepatic clearance models and IVIVE predictions. Clin Pharmacol Ther. 2022. https://doi.org/10.1002/cpt.2525.
Tess DA, Eng H, Kalgutkar AS, Litchfield J, Edmonds DJ, Griffith DA, et al. Predicting the human hepatic clearance of acidic and zwitterionic drugs. J Med Chem. 2020;63(20):11831–44. https://doi.org/10.1021/acs.jmedchem.0c01033.
Berry LM, Li C, Zhao Z. Species differences in distribution and prediction of human V(ss) from preclinical data. Drug Metab Dispos. 2011;39(11):2103–16. https://doi.org/10.1124/dmd.111.040766.
Oie S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci. 1979;68(9):1203–5. https://doi.org/10.1002/jps.2600680948.
Wajima T, Fukumura K, Yano Y, Oguma T. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: oral clearance. J Pharm Sci. 2003;92(12):2427–40. https://doi.org/10.1002/jps.10510.
Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem. 2002;45(13):2867–76. https://doi.org/10.1021/jm0200409.
Arundel PA. A Multi-compartmental model generally applicable to physiologically-based pharmacokinetics. IFAC Proceedings. 1997;30(2):129–33. https://doi.org/10.1016/S1474-6670(17)44557-5.
Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56. https://doi.org/10.1002/jps.10005.
Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918–33. https://doi.org/10.1007/s11095-006-9210-3.
Schmitt MV, Reichel A, Liu X, Fricker G, Lienau P. Extension of the mechanistic tissue distribution model of rodgers and rowland by systematic incorporation of lysosomal trapping: impact on unbound partition coefficient and volume of distribution predictions in the rat. Drug Metab Dispos. 2021;49(1):53–61. https://doi.org/10.1124/dmd.120.000161.
Poulin P, Jones HM, Jones RD, Yates JW, Gibson CR, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets. J Pharm Sci. 2011;100(10):4050–73. https://doi.org/10.1002/jps.22554.
Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci. 2011;100(10):4090–110. https://doi.org/10.1002/jps.22552.
Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 2011;100(10):4074–89. https://doi.org/10.1002/jps.22553.
Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 2009;49(5):513–33. https://doi.org/10.1177/0091270009333209.
Choi GW, Lee YB, Cho HY. Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: in vitro-in vivo extrapolation and allometric scaling. Pharmaceutics. 2019;11(4). https://doi.org/10.3390/pharmaceutics11040168.
Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625–53. https://doi.org/10.1007/BF01059688.
Chen Y, Liu L, Nguyen K, Fretland AJ. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab Dispos. 2011;39(3):373–82. https://doi.org/10.1124/dmd.110.035147.
Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos. 2005;33(9):1304–11. https://doi.org/10.1124/dmd.105.004259.
Sohlenius-Sternbeck AK, Jones C, Ferguson D, Middleton BJ, Projean D, Floby E, et al. Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica. 2012;42(9):841–53. https://doi.org/10.3109/00498254.2012.669080.
Poulin P, Kenny JR, Hop CE, Haddad S. In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J Pharm Sci. 2012;101(2):838–51. https://doi.org/10.1002/jps.22792.
Hultman I, Vedin C, Abrahamsson A, Winiwarter S, Darnell M. Use of HmuREL human coculture system for prediction of intrinsic clearance and metabolite formation for slowly metabolized compounds. Mol Pharm. 2016;13(8):2796–807. https://doi.org/10.1021/acs.molpharmaceut.6b00396.
Chan TS, Yu H, Moore A, Khetani SR, Tweedie D. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model. HepatoPac. Drug Metab Dispos. 2013;41(12):2024–32. https://doi.org/10.1124/dmd.113.053397.
Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford AC, et al. A novel relay method for determining low-clearance values. Drug Metab Dispos. 2012;40(9):1860–5. https://doi.org/10.1124/dmd.112.046425.
Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007–17. https://doi.org/10.1124/dmd.111.042994.
Naritomi Y, Sanoh S, Ohta S. Utility of chimeric mice with humanized liver for predicting human pharmacokinetics in drug discovery: comparison with in vitro-in vivo extrapolation and allometric scaling. Biol Pharm Bull. 2019;42(3):327–36. https://doi.org/10.1248/bpb.b18-00754.
Zanelli U, Michna T, Petersson C. Determination of low intrinsic clearance in vitro: the benefit of a novel internal standard in human hepatocyte incubations. Xenobiotica. 2019;49(4):381–7. https://doi.org/10.1080/00498254.2018.1451010.
Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci. 2004;93(10):2522–34. https://doi.org/10.1002/jps.20169.
Sayama H, Komura H, Kogayu M. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability. Drug Metab Dispos. 2013;41(2):498–507. https://doi.org/10.1124/dmd.112.048819.
Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos. 2005;33(9):1297–303. https://doi.org/10.1124/dmd.105.004143.
Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep. 1970;54(2):95–101.
Wajima T, Yano Y, Fukumura K, Oguma T. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci. 2004;93(7):1890–900. https://doi.org/10.1002/jps.20099.
Li Z, Litchfield J, Tess DA, Carlo AA, Eng H, Keefer C, et al. A physiologically based in silico tool to assess the risk of drug-related crystalluria. J Med Chem. 2020;63(12):6489–98. https://doi.org/10.1021/acs.jmedchem.9b01995.
Di L, Feng B, Goosen TC, Lai Y, Steyn SJ, Varma MV, et al. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos. 2013;41(12):1975–93. https://doi.org/10.1124/dmd.113.054031.
Kunze A, Huwyler J, Camenisch G, Poller B. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos. 2014;42(9):1514–21. https://doi.org/10.1124/dmd.114.058412.49.
Sato M, Toshimoto K, Tomaru A, Yoshikado T, Tanaka Y, Hisaka A, et al. Physiologically based pharmacokinetic modeling of bosentan identifies the saturable hepatic uptake as a major contributor to its nonlinear pharmacokinetics. Drug Metab Dispos. 2018;46(5):740–8. https://doi.org/10.1124/dmd.117.078972.meeting.org/?abstract=9036].
Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–5. https://doi.org/10.1023/a:1018943613122.
Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos. 1998;26(12):1202–12.
Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lave T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci. 2003;92(10):1990–2007. https://doi.org/10.1002/jps.10461.
Gibson CR, Gleason A, Messina E. Measurement of total liver blood flow in intact anesthetized rats using ultrasound imaging. Pharmacol Res Perspect. 2021;9(2):e00731. https://doi.org/10.1002/prp2.731.
Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008;25(12):2869–77. https://doi.org/10.1007/s11095-008-9787-9.
Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos. 2007;35(3):501–2. https://doi.org/10.1124/dmd.106.013359.
Bonn B, Svanberg P, Janefelt A, Hultman I, Grime K. Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary hepatocytes and HepaRG. Drug Metab Dispos. 2016;44(4):527–33. https://doi.org/10.1124/dmd.115.067769.
Kratochwil N, Meille C, Fowler S, Klammers F, Ekiciler A, Molitor B, Simon S, Walter I, McGinnis C, Walther J, Leonard B, Triyatni M, Javanbakht H, Funk C, Schuler F, Lavé, Parrott NJ. Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling. AAPS J. 2017;19:534–50. https://doi.org/10.1208/s12248-016-0019-7.
Schaefer M, Schänzle G, Bischoff D, Süssmuth RD. Upcyte human hepatocytes: a potent in vitro tool for the prediction of hepatic clearance of metabolically stable compounds. Drug Metab Dispos. 2016;44(3):435–44. https://doi.org/10.1124/dmd.115.067348.
Hallifax D, Houston JB. Use of segregated hepatocyte scaling factors and cross-species relationships to resolve clearance dependence in the prediction of human hepatic clearance. Drug Metab Dispos. 2019;47(3):320–7. https://doi.org/10.1124/dmd.118.085191.
Umehara K, Cantrill C, Wittwer M.B., Lenarda E.D., Klammers F, Ekiciler A, Parrott N, Fowler S, Mohammed U. Application of the extended clearance classification system (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction. Drug Metab Dispos. 2020;48(10): 849–860. doi: https://doi.org/10.1124/dmd.120.000133.
Grime K, Paine SW. Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement. Drug Metab Dispos. 2013;41(2):372–8. https://doi.org/10.1124/dmd.112.049312.
Jansen K, Pou Casellas C, Groenink L, Wever KE, Masereeuw R. Humans are animals, but are animals human enough? A systematic review and meta-analysis on interspecies differences in renal drug clearance. Drug Discov Today. 2020;25(4):706–17. https://doi.org/10.1016/j.drudis.2020.01.018.
Paine SW, Menochet K, Denton R, McGinnity DF, Riley RJ. Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos. 2011;39(6):1008–13. https://doi.org/10.1124/dmd.110.037267.
Mathew S, Tess D, Burchett W, Chang G, Woody N, Keefer C, et al. Evaluation of prediction accuracy for volume of distribution in rat and human using in vitro, in vivo, PBPK and QSAR methods. J Pharm Sci. 2021;110(4):1799–823. https://doi.org/10.1016/j.xphs.2020.12.005.
Davies M, Jones RDO, Grime K, Jansson-Lofmark R, Fretland AJ, Winiwarter S, et al. Improving the accuracy of predicted human pharmacokinetics: lessons learned from the AstraZeneca drug pipeline over two decades. Trends Pharmacol Sci. 2020;41(6):390–408. https://doi.org/10.1016/j.tips.2020.03.004.
Hsu F, Chen YC, Broccatelli F. Evaluation of tissue binding in three tissues across five species and prediction of volume of distribution from plasma protein and tissue binding with an existing model. Drug Metab Dispos. 2021;49(4):330–6. https://doi.org/10.1124/dmd.120.000337.
Beaumont K, Smith DA. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel. 2009;12(1):61–71.
van Nuland M, Rosing H, Huitema ADR, Beijnen JH. Predictive value of microdose pharmacokinetics. Clin. Pharmacokinet. 2019;58:1221–36. https://doi.org/10.1007/s40262-019-00769-x.
Jansson-Lofmark R, Hjorth S, Gabrielsson J. Does in vitro potency predict clinically efficacious concentrations? Clin Pharmacol Ther. 2020;108(2):298–305. https://doi.org/10.1002/cpt.1846.
Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012;17(9-10):419–24. https://doi.org/10.1016/j.drudis.2011.12.020.
Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419–31. https://doi.org/10.1038/nrd4309.